All Alzheimer's articles
-
Industry newsIncreased debate over lecanemab
The Lancet has published an editorial encouraging regulators and clinicians to ‘keep an open mind’ about lecanemab, the first drug aimed at slowing the progression of Alzheimer’s disease.
-
Industry newsNICE and EMA say new Alzheimer’s drug is ‘not recommended’
The new draft guidance from NICE states that Lecanemab is ‘not recommended’ and the EMA has recommended the refusal of the marketing authorisation for Leqembi.
-
Industry newsResearchers aim to diagnose Alzheimer’s through blood test
The Blood Biomarker Challenge will aim to determine if a blood test could be used to diagnose people in the early stages of Alzheimer’s disease.
-
Industry newsFDA licence for first drug to treat agitation in Alzheimer’s
Rexulti has become the first FDA-approved treatment for agitation associated with dementia due to Alzheimer’s disease.